学会誌 > 投稿規定

JCEH
  • Journal of Clinical and Experimental Hematopathology (JCEH)

    Published on behalf of the Japanese Society for Lymphoreticular Tissue Research and the Japanese Dendritic Cell Society
    Online ISSN: 1880-9952


    PRODUCT INFORMATION

    Aims and Scope

    The Journal of Clinical and Experimental Hematopathology (JCEH) (the official journal of the Japanese Society for Lymphoreticular Tissue Research and Japanese Dendritic Cell Society) publishes articles describing laboratory and clinical investigations in hematolymphoid system and related field. The JCEH invites submissions under a broad scope of topics relevant to clinical and experimental hematolymphoid research and will consider manuscripts covering all aspects of hematopoiesis, red cells, lymphocytes, phagocytes, dendritic cells, immunobiology and pathophysiology of the hematolymphoid system, hematological malignancies, and transplantation. Manuscript categories include Original Articles, Case Studies, Short Communications, and Letters to the Editor written in English. Original Articles will be accepted for publication with the understanding that they have not been published or submitted elsewhere, and Reviews and Commentaries solicited by the Editor-in-Chief may also be published. For any investigation involving human subjects, informed consent must be obtained from the subject(s) and/or their guardian(s), and this must be clearly stated in the manuscript. Animal experiments should be performed according to the relevant guidelines for the care and use of laboratory animals.

    Peer review processes

    Submitted manuscripts will be sent to peer reviewers. They will generally be reviewed by two experts with the aim of reaching a first decision as soon as possible. Statistical reviewers may be also used where required. Reviewers are asked to declare any competing interests and must agree to open peer review. Reviewers are asked whether the manuscript is scientifically sound and coherent, how interesting it is and whether the quality of the writing is acceptable. Where possible, the final decision is made on the basis that the peer reviewers are in accordance with one another, or that at least there is no em dissenting view. In cases where there is em disagreement either among peer reviewers or between the authors and peer reviewers, advice is sought from a member of the journal's Editorial Board. The journal allows a maximum of three revisions of any manuscript. The ultimate responsibility for editorial decisions lies with the Editor-in-Chief.

    Readership

    Hematologists / dermatologists / pathologists / histologists / epidemiologists / virologists / immunologists / oncologists / occupational and environmental health scientists

    Keywords

    Biology and Immunology of Hematolymphoid Tissues / Reactive, Infectious, and Lymphoproliferative Disorders / Laboratory Methodologies and Technologies / Lymphomas and Lymphoid Leukemias / Myeloma / Plasmacytoma / Lymphoproliferative Disorders (Other Than Overt Neoplasms) / Myeloid Leukemia, Myelodysplastic Syndrome, and Myeloproliferative Disorders / Histiocytic and Dendritic Cell Neoplasms / Non-hematolymphoid Neoplasms

    Indexed/Abstracted in:PubMed (NLM), Google


    EDITORIAL POLICY

    Editor-in-Chief: Professor Naoya Nakamura, Department of pathology, Tokai university school of medicine, 143 Shimokasuya, Isehara-shi, 259-1193, Japan.
    The Editor will review all material submitted for publication. Manuscripts that are considered to be of insufficient priority for publication will receive a prompt decision without further review. All other manuscripts are sent to two Editorial Board Members for peer review, and other expert consultants as needed. Peer reviewer identities are kept confidential. Author identities are not kept confidential. All accepted manuscripts become the permanent property and may not be published elsewhere without written permission from the author(s) and the Academy.

TOP